Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells roden… Read more
Charles River Laboratories (CRL) - Total Liabilities
Latest total liabilities as of September 2025: $4.06 Billion USD
Based on the latest financial reports, Charles River Laboratories (CRL) has total liabilities worth $4.06 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Charles River Laboratories - Total Liabilities Trend (1998–2024)
This chart illustrates how Charles River Laboratories's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Charles River Laboratories Competitors by Total Liabilities
The table below lists competitors of Charles River Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Kingsoft Office Software In
SHG:688111
|
China | CN¥4.50 Billion |
|
Sichuan Tianqi Lithium Industries Inc
SHE:002466
|
China | CN¥22.56 Billion |
|
Hudbay Minerals Inc.
NYSE:HBM
|
USA | $2.84 Billion |
|
Akbank T.A.S
F:AKB2
|
Germany | €2.73 Trillion |
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
USA | $25.97 Billion |
|
Franklin Resources Inc
NYSE:BEN
|
USA | $18.16 Billion |
|
Sunoco LP
NYSE:SUN
|
USA | $12.30 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Charles River Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.18 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Charles River Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Charles River Laboratories (1998–2024)
The table below shows the annual total liabilities of Charles River Laboratories from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.02 Billion | -11.37% |
| 2023-12-31 | $4.54 Billion | -0.94% |
| 2022-12-31 | $4.58 Billion | +3.32% |
| 2021-12-31 | $4.43 Billion | +32.42% |
| 2020-12-31 | $3.35 Billion | +10.60% |
| 2019-12-31 | $3.03 Billion | +20.21% |
| 2018-12-31 | $2.52 Billion | +34.93% |
| 2017-12-31 | $1.87 Billion | +0.42% |
| 2016-12-31 | $1.86 Billion | +42.60% |
| 2015-12-31 | $1.30 Billion | +10.34% |
| 2014-12-31 | $1.18 Billion | +20.50% |
| 2013-12-31 | $979.96 Million | -0.32% |
| 2012-12-31 | $983.14 Million | -4.47% |
| 2011-12-31 | $1.03 Billion | -1.48% |
| 2010-12-31 | $1.04 Billion | +25.82% |
| 2009-12-31 | $830.27 Million | -13.56% |
| 2008-12-31 | $960.47 Million | +2.01% |
| 2007-12-31 | $941.57 Million | -1.21% |
| 2006-12-31 | $953.11 Million | +35.87% |
| 2005-12-31 | $701.48 Million | -38.71% |
| 2004-12-31 | $1.14 Billion | +252.43% |
| 2003-12-31 | $324.75 Million | -0.20% |
| 2002-12-31 | $325.40 Million | +21.03% |
| 2001-12-31 | $268.86 Million | -4.10% |
| 2000-12-31 | $280.35 Million | -40.72% |
| 1999-12-31 | $472.89 Million | +619.90% |
| 1998-12-31 | $65.69 Million | -- |